Scancell Holdings (SCLP) AI Stock Analysis

• Market Cap: £102.38M
• Dividend Yield: N/A
• Average Volume (3M): 644.80K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.26
• Revenue Growth: -100.00%
• EPS Growth: -23.91%
• Country: UK
• Employees: 61
• Sector: Healthcare
• Sector Strength: 59
• Industry: Biotechnology
• EPS (TTM): -0.01
• Shares Outstanding: 1,036,781,400
• 10 Day Avg. Volume: 1,401,408
• 30 Day Avg. Volume: 644,801
• PEG Ratio: -0.02
• Price to Book (P/B): -20.46
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -15.28
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 46 Neutral
• Price Target: ―

Scancell Holdings' overall stock score is heavily influenced by its poor financial performance, characterized by zero revenue and significant losses. However, recent positive clinical trial data and strategic developments in cancer vaccine trials provide a counterbalance, indicating potential for future growth. Technical indicators suggest a mixed trend with short-term bullish momentum, though overbought conditions warrant caution. Valuation remains unattractive, reflecting ongoing financial challenges. Overall, while there are promising developments in the pipeline, the company’s current financial challenges necessitate caution.

Scancell Holdings Business Overview & Revenue Model

Company Description

Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, which is in phase II clinical trial for the treatment of metastatic melanoma; SCIB2 for the treatment of non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2, which targets homocitrullinated cancer antigens. In addition, the company develops SCOV1 and SCOV2 COVIDITY, a prophylactic DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.

How the Company Makes Money

Scancell Holdings makes money primarily through the development and commercialization of its immunotherapy technologies. The company's revenue model includes licensing agreements with pharmaceutical and biotechnology companies, where Scancell grants rights to develop and market its therapeutic products in exchange for upfront payments, milestone payments, and royalties on sales. Additionally, Scancell may receive funding from research grants and partnerships with academic institutions that support the advancement of its technology platforms. These collaborations and partnerships are significant contributors to the company's earnings, helping to finance ongoing research and development activities.

Scancell Holdings Financial Statement Overview

Summary

Scancell Holdings is facing severe financial challenges characterized by zero revenue, consistent losses, and a highly leveraged balance sheet. The negative cash flow situation compounds these issues, indicating that the company may struggle to sustain operations and finance future growth without significant changes or infusions of capital. Caution is advised due to the high-risk financial profile.

Income Statement

Scancell Holdings has faced significant challenges in generating revenue, with zero revenue reported in the most recent period. The company has consistently operated at a loss with a negative net income and gross profit, indicating weak profitability. EBIT and EBITDA margins are also negative, reflecting operational inefficiencies. The lack of revenue growth highlights the company's struggle to penetrate or expand its market presence.

Balance Sheet

The company's balance sheet reveals a concerning financial structure, with negative stockholders' equity indicating potential solvency issues. The debt-to-equity ratio cannot be calculated due to negative equity, but high total debt relative to total assets suggests significant leverage. The equity ratio is negative, signaling that liabilities exceed assets. This poses substantial risk to financial stability and could limit future financing options.

Cash Flow

Scancell Holdings has experienced negative free cash flow, with a downward trend over the past years. The operating cash flow is negative, indicating that the company is not generating sufficient cash from operations to cover its expenses, let alone invest in growth. The free cash flow to net income ratio is not meaningful due to negative values, reflecting persistent cash flow challenges.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
0.00	0.00	5.27M	0.00	0.00	0.00
	Gross Profit
-1.01M	-966.00K	4.75M	-740.00K	-249.00K	-43.00K
	EBIT
-20.69M	-18.27M	-11.92M	-13.30M	-9.75M	-6.78M
	EBITDA
-16.97M	-7.06M	-12.19M	-3.75M	-14.90M	-6.72M
	Net Income Common Stockholders
-15.81M	-5.86M	-11.94M	-2.06M	-15.48M	-5.51M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
9.10M	14.82M	19.92M	41.11M	3.58M	4.56M
	Total Assets
16.61M	23.58M	30.27M	49.06M	8.82M	10.54M
	Total Debt
15.56M	19.87M	19.53M	15.46M	129.00K	129.00K
	Net Debt
6.46M	5.05M	-387.00K	-25.66M	-3.45M	-4.43M
	Total Liabilities
32.10M	27.08M	36.50M	29.57M	1.17M	1.21M
	Stockholders Equity
-15.50M	-3.50M	-6.23M	19.48M	7.65M	9.34M
Cash Flow		Free Cash Flow
-14.25M	-15.84M	-8.34M	-8.55M	-4.80M	-7.04M
	Operating Cash Flow
-14.09M	-15.66M	-8.14M	-7.80M	-4.77M	-7.03M
	Investing Cash Flow
-361.00K	178.00K	81.00K	-741.00K	-13.00K	12.34K
	Financing Cash Flow
10.54M	10.39M	-746.00K	46.08M	3.80M	1.28M

Scancell Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 9.88
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:SCLP, the sentiment is Negative. The current price of 9.88 is above the 20-day moving average (MA) of 9.88, above the 50-day MA of 9.77, and below the 200-day MA of 11.30, indicating a neutral trend. The MACD of 0.10 indicates Positive momentum. The RSI at 49.50 is Neutral, neither overbought nor oversold. The STOCH value of 32.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:SCLP.

Scancell Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.38B	3.27	-45.10%	3.30%	16.81%	0.02%
SCLP	46 Neutral	£102.38M	―	167.16%	―	-100.00%	-23.91%
AVCT		£135.37M	―	-73.02%	―	―	―
IMM		£12.14M	―		―	―	―
OBD	50 Neutral	£7.34M	―	-222.16%	―	24.71%	38.28%
CIZ		£6.94M	―	-272.62%	―	―	―
HEMO		£8.15M	―	-302.41%	―	―	―

Scancell Holdings Corporate Events

Scancell Partners with NHS to Fast-Track Melanoma Vaccine Access

Scancell Holdings has announced a partnership with the NHS Cancer Vaccine Launch Pad to fast-track access for NHS patients into the fourth cohort of its Phase 2 clinical SCOPE study. This study will evaluate the intradermal administration of Scancell’s iSCIB1+, a second-generation DNA cancer vaccine, in patients with advanced melanoma. This collaboration marks Scancell as the first British company to join the CVLP, and iSCIB1+ as the first DNA vaccine in this initiative. The partnership aims to expedite patient access to potentially life-saving treatments and accelerate the clinical development of Scancell’s novel cancer vaccine, which has shown promising efficacy and long-term survival benefits in early trials.

Spark’s Take on GB:SCLP Stock

According to Spark, TipRanks’ AI Analyst, GB:SCLP is a Neutral.

Scancell Holdings’ overall stock score is heavily weighted by its poor financial performance, which is characterized by zero revenue and significant losses. However, the recent positive clinical trial data and strategic developments in cancer vaccine trials provide a counterbalance, indicating potential for future growth. Technical indicators suggest a bearish trend, although the stock is nearing oversold territory, which might indicate a potential rebound. Valuation metrics remain unattractive due to ongoing financial losses. Overall, while there are promising developments in the pipeline, the company’s current financial challenges necessitate caution.

To see Spark’s full report on GB:SCLP stock, click here.

Scancell to Present Promising Phase 2 Melanoma Vaccine Data at AACR 2025

Scancell Holdings has announced that it will present clinical data from its ongoing Phase 2 SCOPE trial of the SCIB1 melanoma vaccine at the 2025 AACR Annual Meeting. The trial, which investigates the use of SCIB1 in combination with checkpoint inhibitors for late-stage melanoma, has shown promising results with an 84% disease control rate and 80% progression-free survival. These findings underscore the potential of SCIB1 to transform melanoma treatment and will guide the design of a future global randomized control registration trial.

Scancell Holdings Grants Share Options to Executive Directors

Scancell Holdings plc has announced the issuance of share options to its executive directors as part of the company’s long-term incentive plan. The options, granted to CEO Phil L’Huillier, CSO Lindy Durrant, and CFO Sath Nirmalananthan, are intended to incentivize and retain key personnel. The options, which have an exercise price of 11.7 pence each, will vest over three years and represent a significant portion of the company’s issued share capital. This strategic move aims to align the interests of the executive team with those of shareholders and fortify Scancell’s positioning in the competitive biopharmaceutical industry.

Scancell Presents Promising Phase 2 Data for Melanoma Vaccine at AACR IO Conference

Scancell Holdings plc announced that translational data from its ongoing Phase 2 SCOPE trial of SCIB1, a DNA plasmid melanoma cancer vaccine, will be presented at the AACR IO conference. The data showcases the efficacy of SCIB1 when combined with nivolumab and ipilimumab, demonstrating an 84% disease control rate and 80% progression-free survival in late-stage melanoma patients. This presentation is expected to validate SCIB1’s potential in cancer immunotherapy, potentially strengthening Scancell’s position in the industry and offering new hope for stakeholders, including patients and investors.